India needs to scale up its daily COVID testing by 10 times: CCMB Director

India has to scale up its daily COVID testing by 10 times to control the current speed of spreading of Coronavirus in the country. Though the mortality rate is very low compared to other countries, there is an urgent need for controlling the speed in its spreading. Hyderabad based Centre for Cellular and Molecular Biology (CCMB) Director Dr Rakesh K Mishra says
that the current level of daily COVID testing should be increased besides the Social Vaccine. Otherwise, he says the present medical facilities will be short of tackling the situation. CCMB Director Dr Rakesh K Mishra informed AIR correspondent that the Virus is spreading at a very high speed and decreasing its speed and immediate detection of infections are the solutions
available currently. Dr Rakesh Mishra further informed that the CCMB Scientists have analysed more than two thousand SARS-Corona Virus genomes from the country to understand the various strains in circulation. He further says the distinct Virus population, called A3i, found earlier in the month of June is disappearing slowly and the A2a has become dominant clade everywhere. At present 70% of all Indian as well as global SARS-CoV-2 genomes fall into this clade. He felt social vaccine which include wearing mask, sanitising hands and maintaining physical distancing will hold good.

Read more at : Parliament passes J&K Official Languages Bill, 2020

Read more at : GOLDEN OPPORTUNITY FOR NON FILERS OF GSTR-4 AND GSTR-10

INSTALL TAX CONCEPT APP

Phase-III human clinical trial of Oxford COVID-19 vaccine begins at Sassoon General Hospital in Pune

The phase-III human clinical trial of the COVID-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India- SII, began today at the state-run Sassoon General Hospital in Pune. According to the dean of Sasoon Hospital, the dose of the Vaccine is to be administered to 150 to 200 volunteers. Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city. The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, being developed by the University of Oxford. Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country. The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of “an unexplained illness” in a participant in the study. However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.

Thanks for reading “Phase-III human clinical trial of Oxford COVID-19
vaccine begins at Sassoon General Hospital in Pune
“

You May Also Like :- GSTR-2B : Features and Advisory

Install Official APP : Click Here to Install

You can also submit article by sending to taxconcept4@gmail.com